Alpha 2.0
Login Register
» Authors » Harrison H Tran

Harrison H Tran

Explore the profile of Harrison H Tran including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 3
Citations 27
Followers 0
Related Specialties
Pharmacology
Chemistry
Co-Authors
Robert M Swift
Victoria M Long
Kimberly Goodyear
Roberto Cacciaglia
Carolina L Haass-Koffler
Lorenzo Leggio
Antonella Loche
Giancarlo Colombo
Carla Lobina
Published In
Eur J Pharm Sci
Data Brief
J Psychopharmacol
Affiliations
Soon will be listed here.
Recent Articles
1.
Administration of the metabotropic glutamate receptor subtype 5 allosteric modulator GET 73 with alcohol: A translational study in rats and humans
Haass-Koffler C, Goodyear K, Loche A, Long V, Lobina C, Tran H, et al.
J Psychopharmacol . 2018 Jan; 32(2):163-173. PMID: 29361897
Preclinical work suggests that GET 73 (N-[4-(trifluoromethyl)benzyl]-4-methoxybutyramide), a novel metabotropic glutamate receptor subtype 5 negative allosteric modulator, may represent a novel pharmacological treatment for alcohol use disorder. Two independent experiments...
2.
Dataset for Phase I randomized clinical trial for safety and tolerability of GET 73 in single and repeated ascending doses including preliminary pharmacokinetic parameters
Haass-Koffler C, Goodyear K, Long V, Tran H, Loche A, Cacciaglia R, et al.
Data Brief . 2017 Dec; 15:407-413. PMID: 29214202
The data in this article outline the methods used for the administration of GET 73 in the first time-in-human manuscript entitled "Phase I randomized clinical trial for the safety, tolerability...
3.
A Phase I randomized clinical trial testing the safety, tolerability and preliminary pharmacokinetics of the mGluR5 negative allosteric modulator GET 73 following single and repeated doses in healthy volunteers
Haass-Koffler C, Goodyear K, Long V, Tran H, Loche A, Cacciaglia R, et al.
Eur J Pharm Sci . 2017 Aug; 109:78-85. PMID: 28778464
Preclinical work suggests that the metabotropic glutamate receptor subtype 5 (mGlu5) may represent a novel target to treat neuropsychiatric disorders, including alcohol use disorder and obesity. The goal of this...